Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Bank of America Health Care Conference 2020 on Tuesday, May 12, 2020 at 10:20 a.m. Eastern time.

Cancer company has lost more than 90% of its market value in past five years Continue reading...

Clovis Oncology, Inc. (NASDAQ: CLVS) shares are trading lower on Tuesday.Late Monday, the company announced a common stock offering of $85 million. The company announced the pricing of 11 million shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share.Clovis Oncology is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations.Clovis Oncology shares were trading down 13.39% at $7.76 on Tuesday. The stock has a 52-week high of $17.61 and a 52-week low of $2.93.Related Links:Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate RemdesivirModerna, Lonza Strike Deal To Manufacture Up To 1 Billion Doses Of Coronavirus Vaccine Candidate AnnuallySee more from Benzinga * Why Dynatrace's Stock Is Trading Higher Today * Why Disney's Stock Is Trading Lower Today * Why Avid Technology's Stock Is Trading Higher Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Clovis (CLVS) delivered earnings and revenue surprises of 0.78% and 1.84%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program

Clovis Oncology (CLVS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of common stock.

On Friday, Clovis Oncology (NASDAQ: CLVS) gained Food and Drug Administration approval of Rubraca for patients with metastatic castration-resistant prostate tumors that have BRCA mutations. By itself, inhibition of PARP doesn't do much, but inhibiting the repair proteins in the presence of mutations in BRCA proteins, which are also responsible for repairing DNA, results in enough damage to cancer cells' DNA that the tumor cells ultimately die. In the pivotal clinical trial used to gain FDA approval, 44% of patients with BRCA prostate cancer responded to Rubraca, defined as a shrinking of the prostate tumor without progression of bone tumors.

Clovis (CLVS) reports first-quarter 2020 results. The company's sole marketed drug, Rubraca, drives revenues. Shares up.

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share, before underwriting discounts and commissions. Clovis Oncology also granted to the underwriters a 30-day option to purchase up to an additional 1,663,500 shares of its common stock on the same terms and conditions.

Q1 2020 Clovis Oncology Inc Earnings Call

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

Shares of small-cap cancer company Clovis Oncology (NASDAQ: CLVS) gained a whopping 33.7% over the course of April, according to data from S&P Global Market Intelligence. Clovis' stock regained its footing last month for two overarching reasons. First and foremost, Clovis' stock lost a noteworthy 15% of its value during March in response to the COVID-19 pandemic.

Company stocks drop on dilution, but monies could benefit shareholders down the line Continue reading...

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2020, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook for the rest of the year.

Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the U.S. Food and Drug Administration (FDA) approved Rubraca® (rucaparib) tablets for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The FDA approved this indication under accelerated approval based on objective response rate (ORR) and duration of response (DOR) data from the multi-center, single arm TRITON2 clinical trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. The TRITON3 clinical trial is expected to serve as the confirmatory study for the Rubraca accelerated approval in mCRPC. Warning and precautions include myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and embryo-fetal toxicity. Please see additional warnings and precautions and select safety information below.i

Clovis' (CLVS) PARP inhibitor, Rubraca, receives approval from the FDA as monotherapy to treat BRCA-mutant metastatic castration-resistant prostate cancer.

Today's 5 Stock Ideas: * Sanofi (SNY) \- A play on a potential coronavirus vaccine. A report Tuesday evening suggested the company was in talks with several countries (including the US) related to advance purchase of the vaccine candidate. * Grubhub (GRUB) \- An earnings play. Will report earnings after the market close on Wednesday. The food delivery space has been viewed by traders as a beneficiary to the coronavirus outbreak. * Clovis Oncology (CLVS) \- A play on an upcoming FDA date. May 15 is set as an action date related to the company's Supplemental New Drug Application for its rubraca prostate cancer drug. * Nintendo (NTDOY) \- An earnings play. Will report quarterly results before the market open on Thursday. * FactSet (FDS) \- A dividend play. The company raised its quarterly dividend from $0.72 to $0.77/share.See more from Benzinga * Benzinga Pro's Top 5 Stocks To Watch For Tues., Apr. 14, 2020: GRUB, EWW, TUP, APPN, WIX * Benzinga Pro's Top 5 Stocks To Watch For Fri., Apr. 3, 2020: USIO, NTDOY, AJRD, AN, OTIS(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Thank you for standing by, and welcome to the Clovis Oncology first-quarter 2020 financial results conference call. Then Dan Muehl, Clovis' chief financial officer, will cover the quarter's financial results in greater detail.